Alimera Sciences Inc is a biopharmaceutical company focused on the research, development, and commercialization of innovative therapies for retinal diseases
The company primarily concentrates on addressing the needs of patients suffering from chronic eye conditions, particularly those related to diabetic macular edema. Alimera aims to enhance visual function and improve the quality of life for individuals with these debilitating conditions through its advanced drug formulations and delivery systems. By leveraging its expertise in ocular therapeutics, the company is committed to advancing care in the field of ophthalmology.
ANI Pharmaceuticals to acquire Alimera Sciences for $5.50 per share in cash, plus a contingent value right of up to $0.50 per share. The transaction is valued at $381 million and is expected to close in Q3 2024.
Potential short squeeze plays gained steam in 2021, continued throughout 2022, and remain a focus of new traders looking for the next huge move. High short interest and steep borrowing costs are among the common traits that could lead to a short squeeze.
Gainers Monogram Orthopaedics Inc. (NASDAQMGRM) shares climbed 148.3% to $29.18 after jumping 62% on Thursday. Monogram Orthopaedics raised $17,216,147 through the sale of 2,374,641 shares of its Class A Common Stock priced at $7.25 per share.
Gainers Monogram Orthopaedics Inc. (NASDAQMGRM) shares surged 163.7% to $30.98 in pre-market trading after jumping 62% on Thursday. Monogram Orthopaedics raised $17,216,147 through the sale of 2,374,641 shares of its Class A
